uniQure N.V. (QURE)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 221
- Market Cap
- $3.4B
About uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
SentiSense also tracks daily options readings for uniQure N.V.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
uniQure N.V. stock analysis, sentiment tracking, and market intelligence on SentiSense.